A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects (2 Years and Older) With Common Warts (Verruca Vulgaris)

Trial Profile

A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects (2 Years and Older) With Common Warts (Verruca Vulgaris)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs VP 102 (Primary)
  • Indications Warts
  • Focus Therapeutic Use
  • Acronyms COVE-1
  • Sponsors Verrica Pharmaceuticals
  • Most Recent Events

    • 06 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top